Roche, Morphosys Drug Cut Peptide Build-Up in Alzheimer’s Study

Roche Holding AG (ROG) and Morphosys AG (MOR)’s experimental Alzheimer’s treatment gantenerumab appeared to reduce the build-up in the brain of beta amyloid plaque thought to be linked to the disease, according to a study published today in Archives of Neurology.

Roche, based in Basel, Switzerland, sponsored the 16-person study, which wasn’t intended to prove whether gantenerumab helps patients. The drug is already being tested in a bigger mid-stage study to help determine its effectiveness for people with early symptoms of Alzheimer’s disease.

To contact the reporter on this story: Naomi Kresge in Berlin at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.